Insulet

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Insulet (PODD) reports record-breaking Q4 earnings, eyes international expansion

Insulet's Q4 2022 earnings call highlighted exceptional revenue growth, strong customer adoption of Omnipod 5, and a focus on customer-centric innovation. While facing challenges with device corrections and FDA approval timelines, the company remains optimistic about revenue growth, margin improvement, and strategic investments in innovation and expansion.

Insulet reports robust Q1 growth, eyes global expansion opportunities

Insulet's Q1 2023 showcased strong financials, driven by Omnipod 5 success and U.S. market growth.
Optimism for future growth, market leadership, and expansion into underpenetrated global markets.
Challenges include declining drug delivery business and the need for continued innovation and market penetration strategies.

Insulet reports robust Q2 earnings, eyes European expansion and innovation

Insulet's Q2 performance exceeded expectations, driven by strong revenue growth and the success of Omnipod 5, showcasing the company's market strength and innovation.
While facing challenges such as inventory management and uncertainties around new products like Omnipod GO, Insulet remains optimistic about its growth trajectory and international expansion.
The company's strategic focus on consumer needs, continuous innovation, and expansion into new markets position it well for sustained leadership and revenue growth in the diabetes management sector.

Insulet excels in Q3 with Omnipod 5 driving growth

Insulet's Q3 performance was robust, driven by Omnipod 5 success.
Confidence in growth outlook, financial strength, and market positioning.
Challenges include competition, timing guidance, and market penetration.
Opportunities lie in basal market expansion and international growth potential.

Insulet (PODD) reports stellar Q4 results and eyes global expansion

Insulet's Q4 2023 performance was robust, driven by strong revenue growth and milestone achievements.
The company's strengths lie in its focus on innovation, market positioning, and strategic partnerships.
Challenges include optimizing resource allocation, reimbursement negotiations, and meeting high demand.
Opportunities for Insulet include expanding digital capabilities, driving innovation, and capturing market growth.

Insulet (PODD) reports record Q3 revenue and outlines growth strategies

Insulet's Q3 performance exceeded expectations with strong revenue and margin growth.
The company's focus on expanding Omnipod 5 platform and international growth is key.
Challenges include maintaining growth rates and sustaining pricing benefits.
Opportunities lie in accelerating international expansion and enhancing customer experience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now indicated for use by people with type 2 diabetes (ages 18 years and older) in the U.S., making it the first and only AID system FDA-cleared for both type 1 and type 2 diabetes management. “Today's announcement represen.

Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

DexCom

Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled Tuesday after a study showed that a popular drug made by Eli Lilly (LLY) significantly lowers the risk of developing type 2 diabetes.

These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 2024 Wells Fargo Healthcare Conference in Boston on Wednesday, September 4, 2024 at 9:30 a.m. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Friday, September 6, 2024 at 8:30 a.m. The Baird.

Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted a grand opening celebration at its new manufacturing facility in Johor Bahru, Malaysia. “Insulet's remarkable growth is driven by our market-leading Omnipod 5, the first and only tubeless automated insulin delivery system in the U.S.,” said Jim Hollingshead, Insulet President and Chief Executive Office.

Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia

Shares of Insulet (PODD) suffered the heaviest losses of any S&P 500 stock on Friday, dropping 8.8% after the maker of insulin management devices suggested new user growth could be lower than previously expected in the second half of 2024, despite topping second-quarter sales estimates.

Insulin Pump Maker Insulet's Stock Slumps on User Growth Concerns

The automated insulin technology developer stock is on track for its largest percentage decline since February.

Insulet Is the Worst Stock in S&P 500 Today, Despite Solid Earnings. Here's Why.

Insulin device maker Insulet Corporation PODD reported a second-quarter adjusted EPS of $0.55 on Thursday, missing the consensus estimate of $0.56. It reported an EPS of $0.38 a year ago.

Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst

Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.

Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised

Insulet Corporation (NASDAQ:PODD ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Maria Chadwick - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Jeff Johnson - Baird Larry Biegelsen - Wells Fargo Margaret Kaczor - William Blair Travis Steed - Bank of America Michael Polark - Wolfe Research Matt Taylor - Jefferies Chris Pasquale - Nephron Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Matthew O'Brien - Piper Sandler Steve Lichtman - Oppenheimer & Co. Joanne Wuensch - Citibank Operator Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.

Insulet Corporation (PODD) Q2 2024 Earnings Call Transcript

Insulet Corp PODD.O on Thursday raised its annual revenue growth forecast but pressures over unutilised inventory clouded the upbeat outlook, sending shares of the insulin device maker down about 3.5% in extended trading.

Insulet inventory pressures cloud annual revenue forecast raise

Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Say

Insulet (PODD) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.38 per share a year ago.

Insulet (PODD) Q2 Earnings Miss Estimates

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2024. Second Quarter Financial Highlights: Second quarter 2024 revenue of $488.5 million, up 23.2%, or 23.4% in constant currency1, compared to $396.5 million in the prior year, exceeds the high end of the Company's guidance range of 18% in const.

Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year

Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Unlocking Q2 Potential of Insulet (PODD): Exploring Wall Street Estimates for Key Metrics

National Vision Hlds

Investors looking for stocks in the Medical - Products sector might want to consider either National Vision (EYE) or Insulet (PODD). But which of these two stocks presents investors with the better value opportunity right now?

EYE vs. PODD: Which Stock Is the Better Value Option?

Insulet reported preliminary second-quarter revenue above Wall Street estimates on Friday, as it benefited from strong demand for its insulin delivery devices.

Insulet expects to beat revenue estimates on strong insulin pump demand

ACTON, Mass.--(BUSINESS WIRE)--Insulet Reports Preliminary Second Quarter 2024 Results.

Insulet Reports Preliminary Second Quarter 2024 Revenue Results

Insulet (PODD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2024 on August 8, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor R.

Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024

EssilorLuxottica SA

Investors interested in stocks from the Medical - Products sector have probably already heard of EssilorLuxottica Unsponsored ADR (ESLOY) and Insulet (PODD). But which of these two stocks offers value investors a better bang for their buck right now?

ESLOY vs. PODD: Which Stock Is the Better Value Option?

Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.

Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today shared positive results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) type 2 diabetes pivotal trial at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida. This landmark study evaluated the impact of AID in a diverse group of people with type 2 diabetes who.

Insulet's SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.

Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5, compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, is now fully available in the U.K. and the Netherlands for individuals aged two years and older with type 1 diabetes. Omnipod 5 is the first and only tubeless automated insulin.

Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made several exciting announcements regarding the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), including its availability in France with Dexcom G6 compatibility, as well as two updates for the U.S. market — the commencement of the Omnipod 5 with Dexcom G7 integration full commercial launch as well.

News for Insulet Stock (PODD)